Risk factors
| Variable . | Group . | N∗ . | pEFS, % . | P value . | pOS, % . | P value . | pRFS, % . | P value . | pDBA, % . | P value . | CIR, % . | P value . | CIR CD19+, % . | P value . | CIR CD19−, % . | P value . | NRM, % . | P value . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, y | 1-6 | 17/15 | 38.2 | .309 | 32.9 | .347 | 43.3 | .130 | 41.1 | .127 | 49.4 | .163 | 42.2 | .172 | 7.2 | .231 | 0.0 | .611 |
| 7-12 | 22/21 | 40.6 | 52.2 | 42.5 | 25.6 | 52.5 | 27.4 | 25.1 | 5.0 | |||||||||
| 13-17 | 11/9 | 48.5 | 72.7 | 59.3 | 60.0 | 40.7 | 29.6 | 11.1 | 0.0 | |||||||||
| 18-25 | 15/12 | 49.4 | 73.5 | 57.0 | 63.0 | 31.5 | 31.5 | 0.0 | 8.3 | |||||||||
| Patient category | Pediatric | 50/45 | 42.1 | .616 | 48.6 | .301 | 46.8 | .438 | 38.4 | .277 | 48.5 | .212 | 31.9 | .810 | 16.7 | .148 | 2.3 | .293 |
| Adults | 15/12 | 49.4 | 73.5 | 57.0 | 63.0 | 31.5 | 31.5 | 0.0 | 8.3 | |||||||||
| Leukemia cytogenetics | Favorable | 7/7 | 57.1 | .387 | 68.6 | .234 | 57.1 | .853 | 31.2 | .348 | 28.6 | .734 | 28.6 | .389 | 0.0 | .080 | 14.3 | .207 |
| Intermediate risk | 33/27 | 35.7 | 42.0 | 43.7 | 58.4 | 48.1 | 23.2 | 24.9 | 4.2 | |||||||||
| High risk | 25/23 | 46.9 | 63.8 | 48.9 | 38.0 | 49.1 | 44.7 | 4.3 | 0.0 | |||||||||
| Leukemia site involvement | Isolated BM | 34/29 | 42.3 | .952 | 54.0 | .707 | 49.6 | .953 | 53.1 | .485 | 43.5 | .938 | 26.2 | .650 | 17.2 | .738 | 3.4 | .217 |
| Isolated CNS | 5/5 | 40.0 | 60.0 | 40.0 | 25.0 | 40.0 | 40.0 | 0.0 | 20.0 | |||||||||
| BM + CNS | 10/9 | 50.8 | 57.1 | 50.8 | 43.2 | 49.2 | 36.5 | 12.7 | 0.0 | |||||||||
| Other | 16/14 | 46.7 | 35.6 | 53.3 | 40.5 | 44.0 | 35.2 | 8.7 | 0.0 | |||||||||
| Time from HSCT to relapse | <6 mo | 22/16 | 18.4 | <.001 | 16.0 | <.001 | 25.2 | .019 | 19.3 | .008 | 68.5 | .026 | 46.6 | .093 | 21.9 | .314 | 6.2 | .475 |
| ≥6 mo | 43/41 | 55.5 | 74.8 | 56.8 | 53.8 | 37.1 | 26.9 | 10.2 | 2.6 | |||||||||
| Remission status at LDC | <5% blasts | 33/31 | 54.1 | .138 | 58.6 | .289 | 57.5 | .317 | 44.9 | .824 | 42.5 | .981 | 28.8 | .860 | 13.7 | .875 | 0.0 | .123 |
| ≥5% blasts | 32/26 | 28.8 | 47.0 | 34.2 | 48.2 | 51.5 | 38.9 | 12.6 | 7.9 | |||||||||
| Cyclophosphamide dose for LDC (mg/m2) | <1000 | 22/18 | 37.7 | .685 | 45.8 | .703 | 46.1 | .610 | 29.4 | .337 | 53.9 | .426 | 53.9 | .211 | 0.0 | .116 | 0.0 | .480 |
| 1000-1499 | 24/22 | 33.6 | 51.2 | 36.6 | 34.9 | 55.8 | 31.9 | 23.9 | 4.8 | |||||||||
| ≥1500 | 16/14 | 59.5 | 62.4 | 63.5 | 79.6 | 29.4 | 15.1 | 14.3 | 0.0 | |||||||||
| Fludarabine dose for LDC (mg/m2) | <120 | 19/16 | 39.9 | .807 | 46.2 | .280 | 47.4 | .949 | 22.3 | .703 | 43.5 | .940 | 36.6 | .538 | 6.9 | .346 | 6.2 | .135 |
| ≥120 | 43/38 | 44.0 | 56.7 | 48.5 | 50.4 | 48.7 | 32.0 | 16.7 | 0.0 |
| Variable . | Group . | N∗ . | pEFS, % . | P value . | pOS, % . | P value . | pRFS, % . | P value . | pDBA, % . | P value . | CIR, % . | P value . | CIR CD19+, % . | P value . | CIR CD19−, % . | P value . | NRM, % . | P value . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, y | 1-6 | 17/15 | 38.2 | .309 | 32.9 | .347 | 43.3 | .130 | 41.1 | .127 | 49.4 | .163 | 42.2 | .172 | 7.2 | .231 | 0.0 | .611 |
| 7-12 | 22/21 | 40.6 | 52.2 | 42.5 | 25.6 | 52.5 | 27.4 | 25.1 | 5.0 | |||||||||
| 13-17 | 11/9 | 48.5 | 72.7 | 59.3 | 60.0 | 40.7 | 29.6 | 11.1 | 0.0 | |||||||||
| 18-25 | 15/12 | 49.4 | 73.5 | 57.0 | 63.0 | 31.5 | 31.5 | 0.0 | 8.3 | |||||||||
| Patient category | Pediatric | 50/45 | 42.1 | .616 | 48.6 | .301 | 46.8 | .438 | 38.4 | .277 | 48.5 | .212 | 31.9 | .810 | 16.7 | .148 | 2.3 | .293 |
| Adults | 15/12 | 49.4 | 73.5 | 57.0 | 63.0 | 31.5 | 31.5 | 0.0 | 8.3 | |||||||||
| Leukemia cytogenetics | Favorable | 7/7 | 57.1 | .387 | 68.6 | .234 | 57.1 | .853 | 31.2 | .348 | 28.6 | .734 | 28.6 | .389 | 0.0 | .080 | 14.3 | .207 |
| Intermediate risk | 33/27 | 35.7 | 42.0 | 43.7 | 58.4 | 48.1 | 23.2 | 24.9 | 4.2 | |||||||||
| High risk | 25/23 | 46.9 | 63.8 | 48.9 | 38.0 | 49.1 | 44.7 | 4.3 | 0.0 | |||||||||
| Leukemia site involvement | Isolated BM | 34/29 | 42.3 | .952 | 54.0 | .707 | 49.6 | .953 | 53.1 | .485 | 43.5 | .938 | 26.2 | .650 | 17.2 | .738 | 3.4 | .217 |
| Isolated CNS | 5/5 | 40.0 | 60.0 | 40.0 | 25.0 | 40.0 | 40.0 | 0.0 | 20.0 | |||||||||
| BM + CNS | 10/9 | 50.8 | 57.1 | 50.8 | 43.2 | 49.2 | 36.5 | 12.7 | 0.0 | |||||||||
| Other | 16/14 | 46.7 | 35.6 | 53.3 | 40.5 | 44.0 | 35.2 | 8.7 | 0.0 | |||||||||
| Time from HSCT to relapse | <6 mo | 22/16 | 18.4 | <.001 | 16.0 | <.001 | 25.2 | .019 | 19.3 | .008 | 68.5 | .026 | 46.6 | .093 | 21.9 | .314 | 6.2 | .475 |
| ≥6 mo | 43/41 | 55.5 | 74.8 | 56.8 | 53.8 | 37.1 | 26.9 | 10.2 | 2.6 | |||||||||
| Remission status at LDC | <5% blasts | 33/31 | 54.1 | .138 | 58.6 | .289 | 57.5 | .317 | 44.9 | .824 | 42.5 | .981 | 28.8 | .860 | 13.7 | .875 | 0.0 | .123 |
| ≥5% blasts | 32/26 | 28.8 | 47.0 | 34.2 | 48.2 | 51.5 | 38.9 | 12.6 | 7.9 | |||||||||
| Cyclophosphamide dose for LDC (mg/m2) | <1000 | 22/18 | 37.7 | .685 | 45.8 | .703 | 46.1 | .610 | 29.4 | .337 | 53.9 | .426 | 53.9 | .211 | 0.0 | .116 | 0.0 | .480 |
| 1000-1499 | 24/22 | 33.6 | 51.2 | 36.6 | 34.9 | 55.8 | 31.9 | 23.9 | 4.8 | |||||||||
| ≥1500 | 16/14 | 59.5 | 62.4 | 63.5 | 79.6 | 29.4 | 15.1 | 14.3 | 0.0 | |||||||||
| Fludarabine dose for LDC (mg/m2) | <120 | 19/16 | 39.9 | .807 | 46.2 | .280 | 47.4 | .949 | 22.3 | .703 | 43.5 | .940 | 36.6 | .538 | 6.9 | .346 | 6.2 | .135 |
| ≥120 | 43/38 | 44.0 | 56.7 | 48.5 | 50.4 | 48.7 | 32.0 | 16.7 | 0.0 |
Risk factor analysis in patients with prior HSCT: estimates at 24 months.
Number of patients for estimation of pEFS and pOS/number of patients for estimation of pRFS, pDBA, CIR, and NRM.